Argitalpenak (84) RUBEN DARIO ARTERO ALLEPUZ argitalpenak

2024

  1. Taurine activates the AKT-mTOR axis to restore muscle mass and contractile strength in human 3D in vitro models of steroid myopathy

    Disease models & mechanisms, Vol. 17, Núm. 4

  2. Therapeutic potential of oleic acid supplementation in myotonic dystrophy muscle cell models

    Biological Research, Vol. 57, Núm. 1

2023

  1. BlockmiR AONs as Site-Specific Therapeutic MBNL Modulation in Myotonic Dystrophy 2D and 3D Muscle Cells and HSALR Mice

    Pharmaceutics, Vol. 15, Núm. 4

  2. CRISPR-Cas9 editing of a TNPO3 mutation in a muscle cell model of limb-girdle muscular dystrophy type D2

    Molecular Therapy - Nucleic Acids, Vol. 31, pp. 324-338

  3. Natural Compound Boldine Lessens Myotonic Dystrophy Type 1 Phenotypes in DM1 Drosophila Models, Patient-Derived Cell Lines, and HSALR Mice

    International Journal of Molecular Sciences, Vol. 24, Núm. 12

  4. Neuroprotective properties of queen bee acid by autophagy induction

    Cell Biology and Toxicology, Vol. 39, Núm. 3, pp. 751-770

  5. Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression

    Molecular Therapy - Nucleic Acids, Vol. 34

  6. Quantitative magnetic resonance imaging assessment of muscle composition in myotonic dystrophy mice

    Scientific Reports, Vol. 13, Núm. 1

  7. The myotonic dystrophy type 1 drug development pipeline: 2022 edition

    Drug Discovery Today, Vol. 28, Núm. 3

2022

  1. Deciphering the Complex Molecular Pathogenesis of Myotonic Dystrophy Type 1 through Omics Studies

    International Journal of Molecular Sciences, Vol. 23, Núm. 3

  2. Moxifloxacin rescues SMA phenotypes in patient-derived cells and animal model

    Cellular and Molecular Life Sciences, Vol. 79, Núm. 8

  3. Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model

    Molecular Therapy - Nucleic Acids, Vol. 27, pp. 1146-1155

  4. Rapid Determination of MBNL1 Protein Levels by Quantitative Dot Blot for the Evaluation of Antisense Oligonucleotides in Myotonic Dystrophy Myoblasts

    Methods in molecular biology (Clifton, N.J.), Vol. 2434, pp. 207-215

  5. Role of miRNAs in muscle atrophy: the myotonic dystrophy paradigm

    MicroRNA: From Bench to Bedside (Elsevier), pp. 331-362

2021

  1. Bioengineered in vitro 3D model of myotonic dystrophy type 1 human skeletal muscle

    Biofabrication, Vol. 13, Núm. 3

  2. Defined d-hexapeptides bind CUG repeats and rescue phenotypes of myotonic dystrophy myotubes in a Drosophila model of the disease

    Scientific Reports, Vol. 11, Núm. 1

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Inhibition of autophagy rescues muscle atrophy in a LGMDD2 Drosophila model

    FASEB Journal, Vol. 35, Núm. 10

  5. Musashi-2 contributes to myotonic dystrophy muscle dysfunction by promoting excessive autophagy through miR-7 biogenesis repression

    Molecular Therapy - Nucleic Acids, Vol. 25, pp. 652-667

  6. Myotonic dystrophy type 1 drug development: A pipeline toward the market

    Drug Discovery Today, Vol. 26, Núm. 7, pp. 1765-1772